These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17649726)

  • 1. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
    Zhang WX; Guo J; Lin BH; Meng SN; Wang XP; Xie Y; Zheng W; Zhang YT; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):41-4. PubMed ID: 17649726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
    Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
    Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
    Berdeja JG; Hess A; Lucas DM; O'Donnell P; Ambinder RF; Diehl LF; Carter-Brookins D; Newton S; Flinn IW
    Clin Cancer Res; 2007 Apr; 13(8):2392-9. PubMed ID: 17438098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
    Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
    Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Chen Z; Freedman MS
    Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alemtuzumab on neoplastic B cells.
    Golay J; Manganini M; Rambaldi A; Introna M
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
    Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
    Gill I; Agah R; Hu E; Mazumder A
    Cancer Res; 1989 Oct; 49(19):5377-9. PubMed ID: 2788499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
    Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    Weng WK; Levy R
    J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation.
    Pfeiffer M; Stanojevic S; Feuchtinger T; Greil J; Handgretinger R; Barbin K; Jung G; Martin D; Niethammer D; Lang P
    Bone Marrow Transplant; 2005 Jul; 36(2):91-7. PubMed ID: 15908973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
    Berinstein N; Levy R
    J Immunol; 1987 Aug; 139(3):971-6. PubMed ID: 3496394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.